Orion's R&D focuses on three core therapy areas

• Central nervous system: medicinal treatments for neurology and psychiatry
• Critical care and Oncology: medicines for cancer treatments as well as medicines used in critical care
• Easyhaler products: medicines for asthma and COPD (Chronic Obstructive Pulmonary Disease)

In addition to these Orion studies and develops medicines for animals and product that have already lost their patent protections so called generics.

Renewed R&D model offers flexibility in operations and cost structure

• In-house research covers mainly early research phases
  i.e. discovery, preclinical phase and clinical phases I and II
  
• Focus on own late-stage research
  - overall number of programmes will be increased
  - risks of individual projects will be balanced
  - new early research molecules will be acquired
  - life-cycle management of own innovative treatments will be improved
  
• Emphasis on research collaboration and partnerships
  - clinical studies are performed globally, Orion’s focus on Europe
  - partnerships are usually sought for clinical phase III at the latest
  - partners are important in marketing authorisation cases in countries outside 
    Europe
  - Orion holds the rights for further develop and market the candidate
    compounds 
• Research and development increasingly supports Proprietary Products and Animal Health in product development and in-liscensing